A versatile targeting system with lentiviral vectors bearing the biotin‐adaptor peptide

Targeted gene transduction in vivo is the ultimate preferred method for gene delivery. We previously developed targeting lentiviral vectors that specifically recognize cell surface molecules with conjugated antibodies and mediate targeted gene transduction both in vitro and in vivo. Although effective in some experimental settings, the conjugation of virus with antibodies is mediated by the interaction between protein A and the Fc region of antibodies, which is not as stable as covalent conjugation. We have now developed a more stable conjugation strategy utilizing the interaction between avidin and biotin.

[1]  S. Minoshima,et al.  Magnetically Targeted Viral Envelopes: A PET Investigation of Initial Biodistribution , 2008, IEEE Transactions on NanoBioscience.

[2]  A. Ting,et al.  Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  A. Chatziioannou,et al.  Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer , 2008, Nature Medicine.

[4]  K. Cichutek,et al.  Targeted cell entry of lentiviral vectors. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  K. Airenne,et al.  Targeting and purification of metabolically biotinylated baculovirus. , 2008, Human gene therapy.

[6]  C. Napoli,et al.  Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer , 2008, Cell.

[7]  Gary Friedman,et al.  High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents , 2008, Proceedings of the National Academy of Sciences.

[8]  R. Reiter,et al.  A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  Bernhard Gleich,et al.  Targeted delivery of magnetic aerosol droplets to the lung , 2007, Nature Nanotechnology.

[10]  David T. Curiel,et al.  Engineering targeted viral vectors for gene therapy , 2007, Nature Reviews Genetics.

[11]  D. Curiel,et al.  Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus , 2007, Gene Therapy.

[12]  I. Chen,et al.  Transient low pH treatment enhances infection of lentiviral vector pseudotypes with a targeting Sindbis envelope. , 2006, Virology.

[13]  O. Laitinen,et al.  Genetically engineered avidins and streptavidins , 2006, Cellular and Molecular Life Sciences CMLS.

[14]  D. Baltimore,et al.  Targeting lentiviral vectors to specific cell types in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Hallek,et al.  Heparan Sulfate Proteoglycan Binding Properties of Adeno-Associated Virus Retargeting Mutants and Consequences for Their In Vivo Tropism , 2006, Journal of Virology.

[16]  H. Heidner,et al.  Targeting Sindbis virus-based vectors to Fc receptor-positive cell types. , 2005, Virology.

[17]  A. Gaggar,et al.  Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity , 2005, Journal of Virology.

[18]  Lily Wu,et al.  Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection , 2005, Nature Medicine.

[19]  U. Häfeli,et al.  Magnetically modulated therapeutic systems. , 2004, International journal of pharmaceutics.

[20]  M. Barry,et al.  Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  M. Roth,et al.  Targeting a retroviral vector in the absence of a known cell-targeting ligand. , 2003, Human gene therapy.

[22]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[23]  M. Barry,et al.  Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  S. Morrison,et al.  An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Mortellaro,et al.  Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.

[26]  S. Neil,et al.  Envelope-targeted retrovirus vectors transduce melanoma xenografts but not spleen or liver. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  I. Chen,et al.  Antibody-Directed Targeting of Retroviral Vectors via Cell Surface Antigens , 2001, Journal of Virology.

[28]  M. Barry,et al.  Metabolic biotinylation of secreted and cell surface proteins from mammalian cells. , 2001, Biochemical and biophysical research communications.

[29]  F. Deist,et al.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.

[30]  Meir Wilchek,et al.  Recombinant NeutraLite Avidin: a non‐glycosylated, acidic mutant of chicken avidin that exhibits high affinity for biotin and low non‐specific binding properties , 2000, FEBS letters.

[31]  S. Morrison,et al.  An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain. , 1999, Journal of immunology.

[32]  J. Young,et al.  Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  I. Chen,et al.  Lentiviral Vectors--the Promise of Gene Therapy Within Reach? , 1999, Science.

[34]  F. Cosset,et al.  Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins , 1996, Journal of virology.

[35]  F. Cosset,et al.  Targeting of retroviral vectors through protease-substrate interactions. , 1996, Gene therapy.

[36]  M. Zoppè,et al.  Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Y. Kan,et al.  Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. , 1994, Science.

[38]  G. Deléage,et al.  Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors , 1994, Journal of virology.

[39]  J Henke,et al.  Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo , 2002, Gene Therapy.